National Storage Mechanism | Additional information
RNS Number : 1790Q
Societe Generale SA
24 February 2021
 

Ap19

 

 

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGSBY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING1% OR MORE

 

1.       KEY INFORMATION

 

Name of person dealing (Note 1)

Société Générale S.A.

Company dealt in

               Willis Towers Watson plc

Class of relevant security to which the dealings being disclosedrelate (Note 2)

US$0.000304635 ordinary shares

Date of dealing

23/02/2021

 

2.         INTERESTS AND SHORT POSITIONS

 

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

 

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

797,465

0.62

1,734

0.00

(2) Derivatives (other than options)

1,428

0.00

8,131

0.01

(3) Options and agreements to purchase/sell

0

0.00

0

0.00

Total

*2,307,521

*1.79

9,865

0.01

                               

* Include the holding of shares 1,508,628 on borrow products

 

               

(b)        Interests and short positions in relevant securities of thecompany, other than the class dealt in (Note 3)

 

Class of relevant security:

Long

Short

 

Number

(%)

Number

(%)

(1) Relevant securities

 

 

 

 

(2) Derivatives (other than options)

 

 

 

 

(3) Options and agreements to purchase/sell

 

 

 

 

Total

 

 

 

 

 

 

Ap20

 

 

1.       DEALINGS (Note 4)

 

(a)      Purchases and sales

 

Purchase/sale

Number of relevant securities

Price per unit USD (Note 5)

Purchase

23

225.83

Purchase

115

225.17

Purchase

76

225.17

Purchase

76

225.17

Purchase

18

224.98

Purchase

16

224.1

Purchase

16

223.9

Purchase

21

226.07

Purchase

42

226.36

Purchase

35

226.36

Purchase

28

226.36

Purchase

42

226.36

Purchase

63

226.26

Purchase

84

226.28

Purchase

24

224.61

Purchase

26

224.4

Purchase

60

225.2

Purchase

12

224.63

Purchase

40

225.21

Purchase

19

224.285

Purchase

13

223.52

Purchase

25

224.98

Purchase

100

225.21

Purchase

20

224.26

Purchase

17

223.53

Purchase

29

224.93

Purchase

14

224.58

Purchase

28

225.25

Purchase

20

225.25

Purchase

10

224.14

Purchase

19

225.23

Purchase

31

225.16

Purchase

6

225.1

Purchase

100

226.36

Purchase

100

225.21

Purchase

1

225

Purchase

10

224.12

Purchase

92

224.57

Purchase

1

225

Purchase

97

225

Purchase

1

225.23

Purchase

21

225.21

Purchase

9

224.73

Purchase

1

225

Purchase

42

225.21

Purchase

100

225.21

Purchase

41

225.15

Purchase

17

224.73

Purchase

6

225.1

Purchase

24

224.61

Purchase

2,280

226.08

Purchase

1,368

226.08

Sale

26

225.14

Sale

74

225.14

Sale

916

226.08

Sale

16

226.08

Sale

1,237

226.08

Sale

1,976

226.08

Total Purchases

5,479

 

Total Sales

4,245

 

 

 

(b)      Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit USD

(Note 5)

 

 

 

 

 

(c)      Options transactions in respect of existing relevant securities

 

 

(i)       Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

 

 

 

 

 

 

 

 

 

(ii)      Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

 

 

 

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

 

Ap21

2.       OTHERINFORMATION

 

Agreements, arrangementsor understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the 

voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition 

or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)                                            No

 

Date of disclosure

24/02/2021

Contact name

Société Générale - Disclosure team

Telephone number

+33 1 42 14 92 74

If a connectedEFM, name of offeree/offeror with which connected

 

If a connectedEFM, state nature of connection (Note 10)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ISEKZLBLFLLBBBE